{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Ardelyx, Inc."},"Symbol":{"label":"Symbol","value":"ARDX"},"Address":{"label":"Address","value":"400 FIFTH AVENUE SUITE 210, WALTHAM, Massachusetts, 2451, United States"},"Phone":{"label":"Phone","value":"+1 510 745-1700"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis."},"CompanyUrl":{"label":"Company Url","value":"https://www.ardelyx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jeffrey W. Jacobs","title":"Chief Scientific Officer"},{"name":"Laura A. Williams","title":"Chief Medical Officer"},{"name":"Michael G. Raab","title":"President, Chief Executive Officer &amp; Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}